Cholestatic Hepatitis Associated With Repaglinide

López-García, Francisco; Borrás, Joaquı́n; Verdú, C.; Vr, Salazar; Ja, Ruiz Macía; Sales, Julianne do Nascimento; Mi, Lucena; Rj, Andrade

doi:10.2337/diacare.28.3.752-a

Cited by 13 publications

(5 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of an electrocardiogram were normal, and the remaining physical examination was unremarkable, except for pallor. Laboratory tests showed: AST 1400 U/L, ALT 1299 U/L, LDH 5990 U/L, creatinine 4.4 mg/dL (0.5-1.5), urea nitrogen 55 mg/dL (7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21), glucose 500 mg/dL (65-110), hemoglobin 13.4 g/dL (12-16), brain natriuretic peptide 62 pg/mL (0-100), troponin I 0.001 ng/mL (0.010-0.040), total bilirubin 1 mg/dL (0.20-1.30) and prothrombin time (international normalized ratio) 1.20. Blood gas analysis showed severe lactic acidosis: pH 7.097 (7.35-7.45), pO 2 80 mm Hg (80-100), pCO 2 11.6 mm Hg , and hepatitis C (virus antibodies) were negative.…”

Section: Case Reportmentioning

confidence: 99%

Erlotinib-Induced Hepatitis Complicated by Fatal Lactic Acidosis in an Elderly Man with Lung Cancer

Pellegrinotti

Fimognari²,

Franco³

et al. 2009

Ann Pharmacother

View full text Add to dashboard Cite

show abstract

Section: Case Reportmentioning

confidence: 99%

Erlotinib-Induced Hepatitis Complicated by Fatal Lactic Acidosis in an Elderly Man with Lung Cancer

Pellegrinotti

Fimognari²,

Franco³

et al. 2009

Ann Pharmacother

View full text Add to dashboard Cite

show abstract

“…There are two case reports on cholestatic hepatitis associated with repaglinide, both are from Spain. 6,7 The putative role of repaglinide in this case of acute cholestasis is strongly supported by its temporal eligibility, the careful exclusion of alternative causes and rapid improvement after drug withdrawal. Multiple comorbidities could account for the transient abnormalities but temporal association strongly implies the drug etiology.…”

Section: Discussionmentioning

confidence: 85%

Repaglinide induced Acute Hepatotoxicity

et al. 2009

View full text Add to dashboard Cite

Repaglinide is considered a safe drug; adverse events are mild to moderate which includes hypoglycemia, headache, nausea, vomiting, diarrhea and dyspepsia as similar to sulphonylureas. This case report describes a rare side effect of repaglinide. In rare cases, elevated liver enzymes have been noted. We report a case of acute hepatotoxicity in a 78 year old woman who developed acute hepatotoxicity while taking repaglinide.Key Words: hepatotoxicity, hypoglycemia, repaglinide,

show abstract

“…[58] As with SUs, rare case reports of either acute hepatotoxicity or cholestatic hepatitis have also been reported with repaglinide. [5960]…”

Section: Methodsmentioning

confidence: 99%

Consensus statement on dose modifications of antidiabetic agents in patients with hepatic impairment

Gangopadhyay

Singh

2017

Indian J Endocr Metab

View full text Add to dashboard Cite

Liver disease is an important cause of mortality in type 2 diabetes mellitus (T2DM). It is estimated that diabetes is the most common cause of liver disease in the United States. Virtually, entire spectrum of liver disease is seen in T2DM including abnormal liver enzymes, nonalcoholic fatty liver disease, cirrhosis, hepatocellular carcinoma, and acute liver failure. The treatment of diabetes mellitus (DM) in cirrhotic patients has particular challenges as follows: (1) about half the patients have malnutrition; (2) patients already have advanced liver disease when clinical DM is diagnosed; (3) most of the oral antidiabetic agents (ADAs) are metabolized in the liver; (4) patients often have episodes of hypoglycemia. The aim of this consensus group convened during the National Insulin Summit 2015, Puducherry, was to focus on the challenges with glycemic management, with particular emphasis to safety of ADAs across stages of liver dysfunction. Published literature, product labels, and major clinical guidelines were reviewed and summarized. The drug classes included are biguanides (metformin), the second- or third-generation sulfonylureas, alpha-glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, and currently available insulins. Consensus recommendations have been drafted for glycemic targets and dose modifications of all ADAs. These can aid clinicians in managing patients with diabetes and liver disease.

show abstract

Cholestatic Hepatitis Associated With Repaglinide

Abstract: A: Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes.

Cited by 13 publications

References 3 publications

Erlotinib-Induced Hepatitis Complicated by Fatal Lactic Acidosis in an Elderly Man with Lung Cancer

Erlotinib-Induced Hepatitis Complicated by Fatal Lactic Acidosis in an Elderly Man with Lung Cancer

Repaglinide induced Acute Hepatotoxicity

Consensus statement on dose modifications of antidiabetic agents in patients with hepatic impairment

Contact Info

Product

Resources

About